Percentage changes in mean brain volume in patients with relapsing-remitting multiple sclerosis receiving disease modifying therapy compared and those receiving placebo.

Lesion and brain volume measures in whole MS patients stratified by ambulatory status, in CA MS and in AA patients stratified byambulatory status.

Jonathan Howard (312009)
Marco Battaglini (300231)
James Scott Babb (312010)
Donatello Arienzo (312011)
Brigitte Holst (312012)
Mirza Omari (312013)
Nicola De Stefano (300236)
Joseph Herbert (312014)
Matilde Inglese (312015)

February 2013

CELs = contrast-enhancing lesions (number); LV = lesion volume (mL); NBV = normalized brain...

Pseudoatrophy of the brain in multiple sclerosis : the effect of therapy on T1 measures of brain water content

Mackie, Emilie Ceschi

November 2010

Magnetic Resonance Imaging (MRI) measures of T₁ relaxation provide a sensitive and reproducible meas...

Brain atrophy in MS patients.

Kaspar-Josche Streitberger (334503)
Ingolf Sack (334504)
Dagmar Krefting (334505)
Caspar Pfüller (216976)
Jürgen Braun (30748)
Friedemann Paul (25657)
Jens Wuerfel (96061)

February 2013

Significantly reduced brain parenchymal volume (a) and brain parenchymal fraction (BPF) (<...

The Effect of Disease-Modifying Drugs on Brain Atrophy in Relapsing-Remitting Multiple Sclerosis: A Meta-Analysis - Fig 3

Pierre Branger (3178446)
Jean-Jacques Parienti (22891)
Maria Pia Sormani (289247)
Gilles Defer (765636)

March 2016

Evolution of the percentage brain volume change up to 48 months (A), from 12 to 48 months (B),...

Evolution of Brain Volume Loss Rates in Early Stages of Multiple Sclerosis

Uher, T
Krasensky, J
Malpas, C
Bergsland, N
Dwyer, MG
Havrdova, EK
Vaneckova, M
Horakova, D
Zivadinov, R
Kalincik, T

May 2021

OBJECTIVE: To describe the dynamics of brain volume loss (BVL) at different stages of relapsing-remi...

Clinical relevance of brain volume measures in multiple sclerosis.

De Stefano, Nicola
Airas, Laura
Grigoriadis, Nikolaos
Mattle, Heinrich P.
O'Riordan, Jonathan
Oreja-Guevara, Celia
Sellebjerg, Finn
Stankoff, Bruno
Walczak, Agata
Wiendl, Heinz
Kieseier, Bernd C

February 2014

Multiple sclerosis (MS) is a chronic disease with an inflammatory and neurodegenerative pathology. A...

Clinical Relevance of Brain Volume Measures in Multiple Sclerosis

DE STEFANO, NICOLA
Laura Airas
Nikolaos Grigoriadis
Heinrich P. Mattle
Jonathan O’Riordan
Celia Oreja Guevara
Finn Sellebjerg
Bruno Stankoff
Agata Walczak
Heinz Wiendl
Bernd C. Kieseier

January 2014

Multiple sclerosis (MS) is a chronic disease with an inflammatory and neurodegenerative pathology. A...

Longitudinal volumetric measures.

Lucy Matthews (4338)
Shannon Kolind (797611)
Alix Brazier (797612)
Maria Isabel Leite (797613)
Jonathan Brooks (797614)
Anthony Traboulsee (194541)
Mark Jenkinson (336068)
Heidi Johansen-Berg (797615)
Jacqueline Palace (25665)

September 2015

(A) Percentage change in brain volume over one year in subject groups. (B) Voxelwise within-group...

Overall analysis of disability progression in placebo-control randomized clinical trials of different disease modifying therapies in patients with relapsing-remitting multiple sclerosis.

Georgios Tsivgoulis (665231)
Aristeidis H. Katsanos (700374)
Nikolaos Grigoriadis (261798)
Georgios M. Hadjigeorgiou (342829)
Ioannis Heliopoulos (700375)
Panagiotis Papathanasopoulos (789573)
Constantinos Kilidireas (700376)
Konstantinos Voumvourakis (700377)
Efthimios Dardiotis (665230)

December 2015

Overall analysis of disability progression in placebo-control randomized clinical trials of diffe...

Detecting treatment effects on brain atrophy in relapsing remitting multiple sclerosis: sample size estimates.

Anderson, Valerie M
Bartlett, Jonathan W
Fox, Nick C
Fisniku, Leonora
Miller, David H

January 2007

Brain atrophy, thought to reflect neuroaxonal degeneration, may be considered an objective marker of...

The effect of disease modifying therapies on brain atrophy in patients with relapsing-remitting multiple sclerosis: a systematic review and meta-analysis.

Georgios Tsivgoulis
Aristeidis H Katsanos
Nikolaos Grigoriadis
Georgios M Hadjigeorgiou
Ioannis Heliopoulos
Constantinos Kilidireas
Konstantinos Voumvourakis

The aim of the present meta-analysis was to evaluate the effect of disease-modifying drugs (DMD) on ...

The Effect of Disease Modifying Therapies on Brain Atrophy in Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis

Georgios Tsivgoulis (665231)
Aristeidis H. Katsanos (700374)
Nikolaos Grigoriadis (261798)
Georgios M. Hadjigeorgiou (342829)
Ioannis Heliopoulos (700375)
Constantinos Kilidireas (700376)
Konstantinos Voumvourakis (700377)

March 2015

<div>BackgroundThe aim of the present meta-analysis was to evaluate the effect of disease-...

Longitudinal brain volume measurement in multiple sclerosis: Rate of brain atrophy is independent of the disease subtype

Kalkers, Nynke F.
Ameziane, Najim
Bot, Joost C.J.
Minneboo, Arjan
Polman, Chris H.
Barkhof, Frederik

October 2002

Background: In multiple sclerosis (MS), brain atrophy depicted by magnetic resonance imaging reflect...

Meta-regression analyses of the percentage change in brain volume over time between treatment subgroups (blue lines) and placebo subgroups (red lines).

Georgios Tsivgoulis (665231)
Aristeidis H. Katsanos (700374)
Nikolaos Grigoriadis (261798)
Georgios M. Hadjigeorgiou (342829)
Ioannis Heliopoulos (700375)
Constantinos Kilidireas (700376)
Konstantinos Voumvourakis (700377)

March 2015

Meta-regression analyses of the percentage change in brain volume over time between treatment sub...

Brain Volume Loss Can Occur at the Rate of Normal Aging in Patients with Multiple Sclerosis Who Are Free from Disease Activity

Joke Temmerman
Floris Van Der Veken
Sebastiaan Engelborghs
Kaat Guldolf
Guy Nagels
Dirk Smeets
Gert-Jan Allemeersch
Lars Costers
Marie B. D’hooghe
Anne-Marie Vanbinst
Jeroen Van Schependom
Maria Bjerke
Miguel D’haeseleer

January 2022

Multiple sclerosis (MS) is a chronic inflammatory demyelinating and degenerative disorder of the cen...

Lesion and brain volume measures in whole MS patients stratified by ambulatory status, in CA MS and in AA patients stratified byambulatory status.

Jonathan Howard (312009)
Marco Battaglini (300231)
James Scott Babb (312010)
Donatello Arienzo (312011)
Brigitte Holst (312012)
Mirza Omari (312013)
Nicola De Stefano (300236)
Joseph Herbert (312014)
Matilde Inglese (312015)

February 2013

CELs = contrast-enhancing lesions (number); LV = lesion volume (mL); NBV = normalized brain...

Pseudoatrophy of the brain in multiple sclerosis : the effect of therapy on T1 measures of brain water content

Mackie, Emilie Ceschi

November 2010

Magnetic Resonance Imaging (MRI) measures of T₁ relaxation provide a sensitive and reproducible meas...

Brain atrophy in MS patients.

Kaspar-Josche Streitberger (334503)
Ingolf Sack (334504)
Dagmar Krefting (334505)
Caspar Pfüller (216976)
Jürgen Braun (30748)
Friedemann Paul (25657)
Jens Wuerfel (96061)

February 2013

Significantly reduced brain parenchymal volume (a) and brain parenchymal fraction (BPF) (<...

The Effect of Disease-Modifying Drugs on Brain Atrophy in Relapsing-Remitting Multiple Sclerosis: A Meta-Analysis - Fig 3

Pierre Branger (3178446)
Jean-Jacques Parienti (22891)
Maria Pia Sormani (289247)
Gilles Defer (765636)

March 2016

Evolution of the percentage brain volume change up to 48 months (A), from 12 to 48 months (B),...

Evolution of Brain Volume Loss Rates in Early Stages of Multiple Sclerosis

Uher, T
Krasensky, J
Malpas, C
Bergsland, N
Dwyer, MG
Havrdova, EK
Vaneckova, M
Horakova, D
Zivadinov, R
Kalincik, T

May 2021

OBJECTIVE: To describe the dynamics of brain volume loss (BVL) at different stages of relapsing-remi...

Clinical relevance of brain volume measures in multiple sclerosis.

De Stefano, Nicola
Airas, Laura
Grigoriadis, Nikolaos
Mattle, Heinrich P.
O'Riordan, Jonathan
Oreja-Guevara, Celia
Sellebjerg, Finn
Stankoff, Bruno
Walczak, Agata
Wiendl, Heinz
Kieseier, Bernd C

February 2014

Multiple sclerosis (MS) is a chronic disease with an inflammatory and neurodegenerative pathology. A...

Clinical Relevance of Brain Volume Measures in Multiple Sclerosis

DE STEFANO, NICOLA
Laura Airas
Nikolaos Grigoriadis
Heinrich P. Mattle
Jonathan O’Riordan
Celia Oreja Guevara
Finn Sellebjerg
Bruno Stankoff
Agata Walczak
Heinz Wiendl
Bernd C. Kieseier

January 2014

Multiple sclerosis (MS) is a chronic disease with an inflammatory and neurodegenerative pathology. A...

Longitudinal volumetric measures.

Lucy Matthews (4338)
Shannon Kolind (797611)
Alix Brazier (797612)
Maria Isabel Leite (797613)
Jonathan Brooks (797614)
Anthony Traboulsee (194541)
Mark Jenkinson (336068)
Heidi Johansen-Berg (797615)
Jacqueline Palace (25665)

September 2015

(A) Percentage change in brain volume over one year in subject groups. (B) Voxelwise within-group...

Overall analysis of disability progression in placebo-control randomized clinical trials of different disease modifying therapies in patients with relapsing-remitting multiple sclerosis.

Georgios Tsivgoulis (665231)
Aristeidis H. Katsanos (700374)
Nikolaos Grigoriadis (261798)
Georgios M. Hadjigeorgiou (342829)
Ioannis Heliopoulos (700375)
Panagiotis Papathanasopoulos (789573)
Constantinos Kilidireas (700376)
Konstantinos Voumvourakis (700377)
Efthimios Dardiotis (665230)

December 2015

Overall analysis of disability progression in placebo-control randomized clinical trials of diffe...

Detecting treatment effects on brain atrophy in relapsing remitting multiple sclerosis: sample size estimates.

Anderson, Valerie M
Bartlett, Jonathan W
Fox, Nick C
Fisniku, Leonora
Miller, David H

January 2007

Brain atrophy, thought to reflect neuroaxonal degeneration, may be considered an objective marker of...

The effect of disease modifying therapies on brain atrophy in patients with relapsing-remitting multiple sclerosis: a systematic review and meta-analysis.

Georgios Tsivgoulis
Aristeidis H Katsanos
Nikolaos Grigoriadis
Georgios M Hadjigeorgiou
Ioannis Heliopoulos
Constantinos Kilidireas
Konstantinos Voumvourakis

The aim of the present meta-analysis was to evaluate the effect of disease-modifying drugs (DMD) on ...

The Effect of Disease Modifying Therapies on Brain Atrophy in Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis

Georgios Tsivgoulis (665231)
Aristeidis H. Katsanos (700374)
Nikolaos Grigoriadis (261798)
Georgios M. Hadjigeorgiou (342829)
Ioannis Heliopoulos (700375)
Constantinos Kilidireas (700376)
Konstantinos Voumvourakis (700377)

March 2015

<div>BackgroundThe aim of the present meta-analysis was to evaluate the effect of disease-...

Longitudinal brain volume measurement in multiple sclerosis: Rate of brain atrophy is independent of the disease subtype

Kalkers, Nynke F.
Ameziane, Najim
Bot, Joost C.J.
Minneboo, Arjan
Polman, Chris H.
Barkhof, Frederik

October 2002

Background: In multiple sclerosis (MS), brain atrophy depicted by magnetic resonance imaging reflect...

Meta-regression analyses of the percentage change in brain volume over time between treatment subgroups (blue lines) and placebo subgroups (red lines).

Georgios Tsivgoulis (665231)
Aristeidis H. Katsanos (700374)
Nikolaos Grigoriadis (261798)
Georgios M. Hadjigeorgiou (342829)
Ioannis Heliopoulos (700375)
Constantinos Kilidireas (700376)
Konstantinos Voumvourakis (700377)

March 2015

Meta-regression analyses of the percentage change in brain volume over time between treatment sub...

Brain Volume Loss Can Occur at the Rate of Normal Aging in Patients with Multiple Sclerosis Who Are Free from Disease Activity

Joke Temmerman
Floris Van Der Veken
Sebastiaan Engelborghs
Kaat Guldolf
Guy Nagels
Dirk Smeets
Gert-Jan Allemeersch
Lars Costers
Marie B. D’hooghe
Anne-Marie Vanbinst
Jeroen Van Schependom
Maria Bjerke
Miguel D’haeseleer

January 2022

Multiple sclerosis (MS) is a chronic inflammatory demyelinating and degenerative disorder of the cen...

Lesion and brain volume measures in whole MS patients stratified by ambulatory status, in CA MS and in AA patients stratified byambulatory status.

Jonathan Howard (312009)
Marco Battaglini (300231)
James Scott Babb (312010)
Donatello Arienzo (312011)
Brigitte Holst (312012)
Mirza Omari (312013)
Nicola De Stefano (300236)
Joseph Herbert (312014)
Matilde Inglese (312015)

February 2013

CELs = contrast-enhancing lesions (number); LV = lesion volume (mL); NBV = normalized brain...

Pseudoatrophy of the brain in multiple sclerosis : the effect of therapy on T1 measures of brain water content

Mackie, Emilie Ceschi

November 2010

Magnetic Resonance Imaging (MRI) measures of T₁ relaxation provide a sensitive and reproducible meas...

Brain atrophy in MS patients.

Kaspar-Josche Streitberger (334503)
Ingolf Sack (334504)
Dagmar Krefting (334505)
Caspar Pfüller (216976)
Jürgen Braun (30748)
Friedemann Paul (25657)
Jens Wuerfel (96061)

February 2013

Significantly reduced brain parenchymal volume (a) and brain parenchymal fraction (BPF) (<...

Percentage changes in mean brain volume in patients with relapsing-remitting multiple sclerosis receiving disease modifying therapy compared and those receiving placebo.

Abstract

Extracted data

Percentage changes in mean brain volume in patients with relapsing-remitting multiple sclerosis receiving disease modifying therapy compared and those receiving placebo.

Abstract

Extracted data

Topics

Related items

Topics

Related items